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Abstract
Background: Escherichia coli is the most common cause of urinary tract infection (UTI). The pathogenic isolates
are becoming increasingly resistant to antibiotics; with a worldwide dissemination of resistant sequence types (ST).
We characterized three different uropathogenic E. coli populations, from non-hospitalized patients to describe
the genetic kinship between resistant and susceptible isolates. We studied the populations by use of multi-locus
sequence typing (MLST) and abbreviated-multi locus variable number of tandem repeat analysis (a-MLVA). Urine
samples submitted for testing, by general practitioners, were identified at Dept. of Clinical Microbiology at Hvidovre
Hospital, Denmark, from Oct. 2011 to July 2012. We included 94 fully susceptible, 94 resistant (non-ESBL) and
98 Extended Spectrum Beta-lactamases- (ESBL)-producing E. coli isolates.
Results: The ESBL population was dominated vastly by ST131 (51 %), ST38 (9 %) and ST69 (6 %). In the resistant
group ST69 (18 %), ST73 (11 %) and ST131 (15 %) were the largest clusters. In the susceptible population more
STs and a-MLVA codes were identified compared to the other groups and ST73 and ST95 were found as the
only clusters with 16 % and 6 %, respectively. Ninety-eight per cent of the ESBL-producing E. coli isolates were
CTX-M-producers.
Conclusion: ST131 dominated the population of community-associated uropathogenic ESBL-producing E. coli, but
was less frequent among non-ESBL-producing E. coli. The fully susceptible E. coli population was a much more
diverse group than the resistant and ESBL-producing E. coli populations. Overall, these findings suggest that
dominant ESBL-producing lineages are derived from UPEC lineages already established in the general UPEC
population.
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Background
Escherichia coli is the most common Gram-negative ex-
traintestinal pathogen and the primary cause of urinary
tract infection (UTI) [1, 2]. It is a highly heterogonous
species with certain lineages becoming increasingly re-
sistant to antibiotics [2–5]. Thus, resistant E. coli isolates
are emerging worldwide and especially E. coli producing
extended-spectrum beta-lactamases (ESBLs) have been
reported numerous times around the world [2, 6]. Now
E. coli isolates primarily produce ESBLs belonging to the
enzyme family CTX-M [2, 6]. The dissemination of
ESBL-producing E. coli in hospital settings as well as in
the community has been reported as spread of extrain-
testinal pathogenic E. coli (ExPEC) belonging to a lim-
ited number of lineages or sequence types (STs) [2, 6].
However, only a few studies have specifically studied the
heterogeneity among susceptible, resistant and ESBL-
producing E. coli [2–4, 6]. Interestingly, dominating ExPEC
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lineages, like ST73 and ST95 continue to be common
causes of UTI, but are rarely multidrug resistant and
seldom associated with ESBL production. These lineages
have previously been sub-typed by different typing
methods showing the existence of several subclones. An
abbreviated-multi locus variable number of tandem repeat
analysis (a-MLVA) method has previously been evaluated
and proved efficient in the characterization of local ESBL-
producing E. coli in hospital settings where the method
typed congruent with multi-locus sequence typing (MLST)
[7]. However, MLST, in spite of its clear advantage of hav-
ing an internationally nomenclature, is laborious and needs
sequencing where MLVA can be used as a fast and low cost
method for screening larger population.
Therefore, we here present a descriptive investigation of
three E. coli populations all from non-hospitalized patients.
The characterization is performed by use of a-MLVA and
subsequent MLST of identified a-MLVA codes.
Methods
Research ethical approvals
Approvals for this study were granted by the Danish
Health and Medicines Authority, Statistics Denmark
(DST) and The Regional Committee of Danish Data Pro-
tection Agency. Patient notification was declared not ne-
cessary by the Regional Committee of Health Research
Ethics Committee (HVH-2012-017, J.nr. 3-3013-230/1/
KWH and H-4-2012-088).
Strain collections
The Department of Clinical Microbiology at Hvidovre
Hospital, Denmark (DCM) provides services to more
than 450 general practitioners in an area of approxi-
mately 950.000 inhabitants. From the 1st of October
2011 to 30th of June 2012 we collected 286 E. coli iso-
lates from patient urine samples, submitted from general
practices. Hence, from non-hospitalized patients, one
unique strain was collected per patient and isolates were
divided into three susceptibility groups: (i) ESBL-producing
E. coli, (ii) E. coli resistant to at least one of 17 tested anti-
biotic (ampicillin, cefuroxime, aztreonam, ampicillin/clavu-
lanic acid, piperacillin/tazobactam, mecillinam, ceftazidime,
cefpodoxime, meropenem, ciprofloxacin, sulfamethoxazole,
trimethoprim, tetracycline, gentamicin, tobramycin, nitro-
furantoin, fosfomycin) but without an ESBL phenotype and
(iii) fully susceptible E. coli. Thus, in this study we included
98 ESBL-producing E. coli isolates, 94 resistant isolates
(non-ESBL) and 94 fully susceptible E. coli.
Strain identification and susceptibility testing
The UPEC isolates were all identified at species level by
MALDI-TOF MS (Bruker, Germany) and antimicrobial
susceptibility testing was performed by Disk Diffusion Test
Methodology as described in the European Committee on
Antimicrobial Susceptibility Testing (EUCAST, Version 1.0,
December 18, 2009) or by The Vitek 2 automated system by
use of cards AST-N209 and AST-N122 (bioMérieux,
France). Methods were performed according to guidelines
of DCM in agreement with direction from manufacturers
and as described elsewhere [8–11]. The ATCC 25922 E. coli
was used for quality control and susceptibility interpreted
as recommended by EUCAST (www.eucast.org/clinical_
breakpoints/). Resistance to cefpodoxime was used as an
indicator for ESBL-production. Isolates resistant to cefpo-
doxime therefore had potential ESBL phenotypes identified
by a double-disk diffusion method; here performed as
combined-disk diffusion using a AmpC+ESBL detection
set (MAST®, Merseyside, UK) as previously described [10].
Molecular characterization
ESBL-genotyping
ESBL-producing E. coli, phenotypically recognized by
the double-disk diffusion MAST® test, were screened for
the presence of blaCTX-M genes by multiplex PCR
assay, detecting alleles encoding the five CTX-M groups
1, 2, 8, 9 and 25 as previously described [7, 12]. Positive
samples were re-amplified and products were sequenced
to identify the exact genotypes of CTX-M [7, 12].
MLVA and MLST
All included isolates were typed using a-MLVA, with PCR
amplification of six variable number of tandem repeats
(VNTR) loci, as described by Nielsen et al. [7]. In short,
PCR were done as singleplex PCR with unlabelled primers.
Subsequent size determination were done using an auto-
mated capillary electrophoresis system (QIAxcel, Qiagen)
and a high-resolution cartridge [7]. Each of the VNTR loci
was manually binned depending on size and assigned a
number. As result each isolate were given a six-digit a-
MLVA code. For isolates without a measured band size, for
a VNTR locus, PCR amplification was performed twice for
the given locus. The identified codes were primarily trans-
lated to STs by an in-house library, but to further confirm
our findings, at least one isolate from each identified a-
MLVA code were verified by MLST, with the exception of
one a-MLVA code. In groups with several isolates having
identical a-MLVA codes, we included isolates with extreme
band sizes within bins, to effectively cohere clusters. In the
ESBL population we furthermore included isolates, belong-
ing to ST131, for O-serogrouping, performed by GlycoV-
axyn. In all, MLST was performed on 31 isolates from the
ESBL population, on 45 isolates from the resistant popula-
tion and on 52 isolates from the susceptible population.
MLST was done using the Achtmann MLST scheme with
PCR and sequencing of seven housekeeping genes followed
by assignment of an allelic number from the MLST-
database (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) [7, 13].
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Results
Characterization of the E. coli populations
We defined a cluster as three or more isolates identified
as the same ST or a-MLVA code. a-MLVA was per-
formed on all isolates and MLST was performed to link
a-MLVA codes to an international known nomenclature.
Used in this way a-MLVA divides isolates before more
laborious and costly typing by MLST. A total of 83
unique a-MLVA codes were identified among the 286
isolates (Additional file 1). In several occasions one ST
was subdivided into more than one a-MLVA codes and
complex situations existed where the a-MLVA method
did not distinguish between two or more STs as has
been seen previously with this current a-MLVA method
as well as with other MLVA methods [7, 14] (Additional
file 1). Results from the MLST are presented in Fig. 1a–c
and a maximum likelihood tree showing all ST’s found
in the three populations is found in Fig. 2. We found 72
different sequence types in the 141 isolates typed by
MLST. We discovered ten STs, not previously identified,
here labelled “New ST 1–10". We detected a large
ST131 cluster with one a-MLVA code primarily belong-
ing to O25, all of which were resistant to ciprofloxacin.
A minor ST131 cluster, with another a-MLVA code be-
longing to O16 was likewise detected, but here no iso-
lates showed resistance to ciprofloxacin.
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Fig. 1 Distribution of major clusters of sequence types among the three E. coli populations. We show STs making up 2 % or more of
isolates—except for ST131 in the susceptible population. Single STs = Percentage of STs found in one isolate only. a ESBL-producing E. coli. STs
found but not shown: ST14, ST62, ST88, ST120, ST224, ST315, ST354, ST428, ST636 and ST2852. There was not found a unique a-MLVA code for
ST746/ST1598 and ST101/ST448. b Resistant (non-ESBL) E. coli. STs found but not shown: ST14, ST38, ST62, ST80, ST135, ST141, ST362, ST372,
ST393, ST457, ST648, ST978, ST1597, New ST (1 and 2) and ST117/ST1177. There was not found a unique a-MLVA code for ST10/ST2279, ST88/New
ST 3 and ST117/ST1177. c Susceptible E. coli. STs found but not shown: ST12, ST14, ST38, ST48, ST59, ST62, ST80, ST101, ST127, ST141, ST162,
ST405, ST410, ST420, ST501, ST538, ST540, ST582, ST589, ST681, ST714, ST1161, ST1331, ST1444, ST1858, ST3672, ST4235, New ST (4–10) and
ST3846. There was not found a unique a-MLVA code for ST10/93/540/New ST and ST141/998
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Antibiotic resistance patterns
Results of antibiotic susceptibility testing are found in
Figs. 3 and 4. Generally the ESBL population showed
high levels of resistance with 100 % of the isolates show-
ing resistance towards three or more of the tested antibi-
otics. In the resistant population 66 % of the isolates
were resistant to ≥3 of the antibiotics. All isolates were
susceptible to meropenem and most to mecillinam (97–
99 %), fosfomycin (96–97 %), nitrofurantoin (93–96 %),
and piperacillin/tazobactam (92–95 %). Figure 3 indicates
that resistant (non-ESBL) ST131 have a broader spectrum
of resistance than resistant (non-ESBL) ST73 and ST69.
ESBL-genotyping
We found that 98 % of the ESBL-producing E. coli iso-
lates were positive for the presence of a blaCTX-M.
blaCTX-M group 1 dominated with 73 % of all isolates
carrying this type and 54 % produced CTX-M-15. A
total of 24 % of isolates belonged to CTX-M group 9.
Unknown7
95
80
73
1331
582
3846
420
1161
Unknown6
1444
4235
3672
12
372
127
1858
1193
405
14
141
998
2279
131
1597
538
357
428
681
589
135
636
117
Unknown5
10
617
Unknown8
48
93
Unknown3
Unknown4
746
1598
162
540
223
101
58
88
410
Unknown2
2852
448
120
224
62
457
354
Unknown1
648
59
714
501
Unknown9
Unknown10
38
1177
315
362
69
393
Fig. 2 Maximum likelihood tree showing all ST’s found in the three
populations. We do not show the number of isolates belonging
to each ST. = ST´s found in the susceptible population only.
= ST´s found in the resistant, non-ESBL population only. = ST´s
found in the ESBL population only. = ST´s found in the susceptible
and resistant, non-ESBL populations. = ST´s found in all three popu-
lations. = ST´s found in the two resistant populations
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Fig. 3 Resistance patterns for the resistant populations
Fig. 4 Percentages of isolates resistant to chosen antibiotics used for
oral administration. Shown are resistance patterns for three common
UPEC ST lineages, where all isolates are non-ESBL-producers but
present in either the susceptible or resistant population. N: ST131 = 17,
ST73 = 25, ST69 = 20
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Discussion
This study was carried out to describe the diversity
among susceptible, resistant (non-ESBL) and ESBL-
producing E. coli. MLST was performed to link a-MLVA
codes to an international known nomenclature. Overall
we found ST131, ST73 and ST69 to be the dominating
lineages among all isolates, in accordance with previous
studies [15]. The resistant (non-ESBL) ST131 showed a
broader spectrum of resistance than the other prevalent
STs in this population (ST73 and ST69) (Fig. 3), which
has also been previously described by Horner et al. [15].
We found that ESBL-producing E. coli, resistant E. coli
and susceptible E. coli in turn were dominated by differ-
ent lineages based on a-MLVA codes and STs (Fig. 1). In
general, the susceptible E. coli population was a much
more diverse group of isolates with more STs and
smaller clusters (Fig. 1 and Additional file 1). The ST-
clusters in this population were subdivided by a-MLVA,
emphasizing a higher level of diversity. The resistant E.
coli and ESBL-producing E. coli were found in larger
clusters. Especially the ESBL-population was a more
homogenous population with fewest a-MLVA codes and
STs (Fig. 1). We found that ST131 completely dominated
this ESBL-producing E. coli population, as previously
seen in the Copenhagen area [7, 16]. Only a single
ST131 isolate was found among the susceptible isolates
and 14 detected in the resistant population (Fig. 1). Cor-
responding well with preceding reports, we found that
most ST131 isolates belong to serogroup O25 and a
minor part being identified as O16 [16, 17]. It should be
noted, that the ESBL-population is likely a more selected
group, allowing us to detect less successful STs with lim-
ited impact as UPEC, which will influence the estab-
lished representation of diversity in this group. However,
we speculate if resistance in different E. coli populations
are somewhat defined by intrinsic differences in distinct
E. coli lineages, making a limited number of UPEC ST-
lineages capable of obtaining and spreading blaCTX-M.
Some lineages successfully acquire and maintain differ-
ent types of mobile resistance genes like ST69 and espe-
cially ST131, while other E. coli lineages remain fairly
susceptible and rarely take up plasmids, as seen with
ST73 and ST95 [3, 4]. ST131 could be one of the UPEC
lineages, among these resistant and ESBL-producing
isolates, with the highest ability to colonize the hu-
man gut, creating a high prevalence in these popula-
tions. Nevertheless, production of ESBLs are found
among specific UPEC present, to some extent, in all
populations. Thus, antibiotic selection creates a less
varied population structure of related isolates while
antibiotic free environments allows for competition
and diverse non-related population structure [18].
The UPEC we found in our three populations have
been found in other population-studies of E. coli
isolates causing bacteraemia, strongly indicating that
E. coli isolates capable of one invasive disease can
cause severe invasive infections, independent of
antibiotic susceptibility [15]. Finally, our results are in line
with the reports, using more than one method of
characterization, identifying susceptible ST-lineages as
more heterogeneous populations [2, 6, 17, 19].
One of the major limitations of this study is the in-
complete separation of all STs. However, this also pro-
vides high discriminatory power in the ability to separate
closely related ST-lineages and thereby describe E. coli
populations in detail. Yet, the missing identification of
STs are unlikely to cause bias in our overall conclu-
sion as the prevalence and identification of the major
lineages in the three populations are unique. The a-
MLVA typing method was successful in the charac-
terization and sub-division of some large cluster of
ST-lineages. The study is additionally limited by the
relatively small number of isolates characterized and
the limited time period of collection, which does not
allow us to identify any fluctuation in dominant lineages
of non-ESBL populations.
Conclusions
In conclusion; this study was carried out to describe the
diversity among susceptible, resistant (non-ESBL) and
ESBL-producing E. coli. Overall we found ST131, ST73
and ST69 to be the dominating lineages among all iso-
lates, in accordance with previous studies [15]. ST131
was able to effectively dominate the ESBL-producing
UPEC and seems to be a specialized UPEC adapted as
an efficient resistant and ESBL-producing lineage, sus-
tainable in the community once present. The findings
we present here strongly suggest that the observed dis-
semination of ESBL-producing E. coli are due to the
spread of certain UPEC lineages already present in the
general UPEC population [3]. Such lineages seems able
to dominate the ESBL-population and it is likely that the
spread of resistance occurs due to selection of previously
specialized UPEC with limited fitness loss due to ESBL-
production [4].
Availability of supporting data
We have not deposited additional or supporting data
online, but we present the data on which our findings
are based in the Additional file 1 for the present paper.
Additional file
Additional file 1: The additional data contains the characterization of
the E.coli populations. It shows the distribution of a-MLVA codes and
Sequence Types in details in three tables: Additional file 1: S1 to S3. Here
we show the number of isolates found in each cluster of STs and a-MLVA
codes, respectively. Furthermore, we present each ST and the
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corresponding a-MLVA code (or a-MLVA codes in case more than one
a-MLVA code was identified for a specific ST). In addition, we show cases
where more than one ST was identified by the same a-MLVA. Finally, for
the ESBL-population, we show the ESBL genotype identified within each
a-MLVA code. (PDF 439 101 kb)
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